What is a potential serious adverse effect of trametinib that patients should be aware of?

Trametinib, a medication used in the treatment of certain types of cancer, is associated with a range of adverse effects, one of which is rhabdomyolysis. This condition involves the breakdown of muscle tissue, leading to the release of muscle fiber contents into the bloodstream, which can result in serious complications, including kidney damage.

Patients taking trametinib should be educated about the signs and symptoms of rhabdomyolysis, which can include muscle pain, weakness, swelling, and dark, tea-colored urine. Recognizing these symptoms early allows for prompt medical intervention, which is critical in preventing more severe outcomes like acute kidney injury.

While trametinib has other potential adverse effects, the significance of rhabdomyolysis as a serious and possibly life-threatening condition necessitates that it be highlighted for patients. Other options listed might relate to concerns in oncology pharmacotherapy, but rhabdomyolysis is specially noted for its urgency and potential severity in connection to trametinib therapy.